Patents by Inventor Manuel Yepes
Manuel Yepes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10676527Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: February 12, 2018Date of Patent: June 9, 2020Assignees: Ludwig Institute for Cancer Research Ltd., The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Publication number: 20180222984Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: February 12, 2018Publication date: August 9, 2018Applicants: Ludwig Institute for Cancer Research Ltd, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 9926372Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: October 6, 2016Date of Patent: March 27, 2018Assignees: Ludwig Institute for Cancer Research Ltd, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Publication number: 20170152318Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: October 6, 2016Publication date: June 1, 2017Applicants: The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 9487579Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: May 20, 2014Date of Patent: November 8, 2016Assignees: LUDWIG INSTITUTE FOR CANCER RESEARCH, UNIVERSITY OF MARYLAND, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Publication number: 20140255397Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: May 20, 2014Publication date: September 11, 2014Applicants: Ludwig Institute for Cancer Research, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 8765671Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: February 28, 2012Date of Patent: July 1, 2014Assignees: Ludwig Institute for Cancer Research, University of Maryland, The Regents of the University of MichiganInventors: Ulf Eriksson, Daniel Lawrence, Enming Joe Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
-
Publication number: 20120156187Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: February 28, 2012Publication date: June 21, 2012Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH, THE REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Ulf Eriksson, Daniel Lawrence, Enming Joe Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
-
Patent number: 8147828Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: April 17, 2007Date of Patent: April 3, 2012Assignees: Ludwig Institute for Cancer Research, University of Maryland, The Regents of the University of MichiganInventors: Ulf Eriksson, Daniel Lawrence, Enming Joe Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
-
Publication number: 20070280940Abstract: The present invention is directed to compositions and methods for treating cerebral edema and cell death in neurological conditions characterized by disruption of the architecture of the neurovascular unit with increase in the permeability of the NVU, particularly for treating stroke. One aspect of the present invention relates to a composition comprising an agent that interferes with a TWEAK-mediated signaling pathway. Another aspect of the present invention relates to a method of using a composition which comprises an agent that inhibits. Fn14 activity or Fn14 expression for the prevention and/or treatment of cerebral edema and cell death occurring in certain neurological conditions such as cerebral ischemia.Type: ApplicationFiled: November 8, 2005Publication date: December 6, 2007Applicant: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Jeffrey Winkles, Manuel Yepes
-
Publication number: 20070265203Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: April 17, 2007Publication date: November 15, 2007Applicant: Ludwig Institute for Cancer ResearchInventors: Ulf Eriksson, Daniel Lawrence, Enming Su, Dudley Strickland, Manuel Yepes, Linda Fredriksson
-
Publication number: 20070259806Abstract: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.Type: ApplicationFiled: June 4, 2007Publication date: November 8, 2007Applicants: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Gregg Hastings, Timothy Coleman, Patrick Dillon, Daniel Lawrence, Maria Sandkvist, Manuel Yepes, Michael Wong
-
Patent number: 7235529Abstract: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.Type: GrantFiled: January 7, 2004Date of Patent: June 26, 2007Assignees: Human Genome Sciences, Inc., The Regents of the University of MichiganInventors: Timothy A. Coleman, Daniel A. Lawrence, Manuel Yepes
-
Patent number: 7087574Abstract: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.Type: GrantFiled: January 31, 2003Date of Patent: August 8, 2006Assignees: Human Genome Sciences, Inc., The American Red CrossInventors: Daniel A. Lawrence, Manuel Yepes, Maria Sandkvist, Timothy A. Coleman, Michael K. K. Wong
-
Publication number: 20050019329Abstract: The present invention is a method of reducing vascular permeability in tissue of a subject comprising inhibiting the activity of serine proteinase tissue-type plasminogen activator (tPA). This tPA activity which increases permeability of the tissue in a subject results in edema in the tissue is separate from tPA's thrombolytic activity. The present invention more specifically relates to administering an amount of a tPA inhibitor sufficient to reduce the vascular permeability increasing activity of tPA in a subject. Useful tPA inhibitors for the present method are neuroserpin, mutant neuroserpin, wild-type PAI-1, mutant PAI-1, an antibody that binds to tPA, an antibody that binds to the low-density lipoprotein (LDL) receptor or a low-density lipoprotein (LDL) receptor family antagonist.Type: ApplicationFiled: May 20, 2004Publication date: January 27, 2005Inventors: Daniel Lawrence, Manuel Yepes, Dudley Strickland
-
Publication number: 20040203101Abstract: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.Type: ApplicationFiled: January 7, 2004Publication date: October 14, 2004Applicants: Human Genome Sciences, Inc., The American Red CrossInventors: Gregg A. Hastings, Timothy A. Coleman, Patrick J. Dillon, Daniel A. Lawrence, Maria Sandkvist, Manuel Yepes, Michael K. K. Wong
-
Publication number: 20040038880Abstract: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.Type: ApplicationFiled: January 31, 2003Publication date: February 26, 2004Applicants: Human Genome Sciences, Inc., The American Red CrossInventors: Daniel A. Lawrence, Manuel Yepes, Maria Sandkvist, Timothy A. Coleman, Michael K.K. Wong
-
Publication number: 20020165147Abstract: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.Type: ApplicationFiled: November 13, 2001Publication date: November 7, 2002Inventors: Manuel Yepes, Daniel A. Lawrence, Timothy A. Coleman
-
Publication number: 20020143165Abstract: The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.Type: ApplicationFiled: September 21, 2001Publication date: October 3, 2002Applicant: Human Genome Sciences, Inc.Inventors: Daniel A. Lawrence, Manuel Yepes, Maria Sandkvist, Michael K. K. Wong, Timothy A. Coleman